{'52WeekChange': 0.40547943,
 'SandP52WeekChange': None,
 'address1': '30 Technology Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.21,
 'askSize': 2200,
 'averageDailyVolume10Day': 641725,
 'averageVolume': 1073931,
 'averageVolume10days': 641725,
 'beta': None,
 'beta3Year': None,
 'bid': 5.08,
 'bidSize': 1000,
 'bookValue': -0.62,
 'category': None,
 'circulatingSupply': None,
 'city': 'Warren',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.16,
 'dayLow': 4.92,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.993,
 'enterpriseToRevenue': 4.122,
 'enterpriseValue': 200873664,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.9407144,
 'fiftyTwoWeekHigh': 10,
 'fiftyTwoWeekLow': 1.41,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 27646954,
 'forwardEps': -1.36,
 'forwardPE': -3.7536764,
 'fromCurrency': None,
 'fullTimeEmployees': 232,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.13683,
 'heldPercentInstitutions': 0.57502,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aquestive.com',
 'longBusinessSummary': 'Aquestive Therapeutics, Inc., a specialty '
                        'pharmaceutical company, focuses on identifying, '
                        'developing, and commercializing various products to '
                        'address unmet medical needs. The company markets '
                        'Sympazan, an oral soluble film formulation of '
                        'clobazam for the treatment of lennox-gastaut '
                        'syndrome; Suboxone, a sublingual film formulation of '
                        'buprenorphine and naloxone for the treatment of '
                        'opioid dependence; and Zuplenz, an oral soluble film '
                        'formulation of ondansetron for the treatment of '
                        'nausea and vomiting associated with chemotherapy and '
                        'post-operative recovery in the United States and '
                        'internationally. Its proprietary product candidates '
                        'comprise Libervant, a buccal soluble film formulation '
                        'of diazepam for the treatment of recurrent epileptic '
                        'seizures; and Exservan, an oral soluble film '
                        'formulation of riluzole for the treatment of '
                        "Amyotrophic Lateral Sclerosis. The company's "
                        'proprietary pipeline of complex molecule products '
                        'include AQST-108, a sublingual film formulation of '
                        'epinephrine for the treatment of anaphylaxis; and '
                        'AQST-305, a sublingual film formulation of octreotide '
                        'for the treatment of acromegaly and neuroendocrine '
                        'tumors. It also develops AQST-119, an oral soluble '
                        'film formulation of tadalafil for the treatment of '
                        'erectile dysfunction; and APL-130277, a sublingual '
                        "film using apomorphine to treat parkinson's disease. "
                        'Aquestive Therapeutics, Inc. was founded in 2004 and '
                        'is headquartered in Warren, New Jersey.',
 'longName': 'Aquestive Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 171439680,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_8142504',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -68050000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.11,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '908-941-1900',
 'previousClose': 5.13,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 3.5180826,
 'profitMargins': -1.39644,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.16,
 'regularMarketDayLow': 4.92,
 'regularMarketOpen': 5.11,
 'regularMarketPreviousClose': 5.13,
 'regularMarketPrice': 5.11,
 'regularMarketVolume': 578430,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 33582700,
 'sharesPercentSharesOut': 0.051,
 'sharesShort': 1713560,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1321520,
 'shortName': 'Aquestive Therapeutics, Inc.',
 'shortPercentOfFloat': 0.088199995,
 'shortRatio': 1.95,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'AQST',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.474,
 'twoHundredDayAverage': 4.225288,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '22956725-87cb-39ad-9e8b-1bc1480b8337',
 'volume': 578430,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aquestive.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '07059'}